News Column

INTERNATIONAL STEM CELL CORP FILES (8-K) Disclosing Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits

June 12, 2014


On June 11, 2014, International Stem Corporation (the "Company") entered into a series of warrant exchange agreements (the "Warrant Exchange Agreements") with the holders of its Series A Warrants and Placement Agent Warrants that had been issued by the Company pursuant to the Form S-1 Registration Statement relating to the public offering consummated in July 2013. Under the Warrant Exchange Agreements, the Company agreed to issue a total of 44,665,783 shares of common stock (the "Exchange Shares") to the warrant holders in exchange for the cancellation of warrants to purchase 36,554,822 shares of common stock and the placement agent warrants for purchase of 666,666 shares of common stock and warrants. Dr. Andrey Semechkin and Dr. Ruslan Semechkin, each of whom is a director and executive officer of the company, participated in the exchange on the same terms as the other warrant holders, agreeing to exchange warrants to purchase 10,088,154 shares for 12,105,784 shares of common stock. The closing of the warrant exchanges is expected to occur on June 16, 2014. The foregoing summary of the Warrant Exchange Agreements is qualified in its entirety by reference to the full text of the form of Warrant Exchange Agreements filed as Exhibit 10.1 to this Report on Form 8-K.


See Item 1.01 regarding the issuance of 44,665,783 shares of common stock in exchange for outstanding warrants. These shares will be issued in exchange for previously issued securities in a transaction exempt from registration pursuant to Section 3(a)(9) of the Securities Act.

Since May 2, 2014 (the date as of which the number of outstanding shares of common stock was reported in the Company's most recent report on Form 10-Q), the Company has also sold a total of 3,333,333 shares of common stock to directors and executive officers in a private placement transaction made in reliance upon the exemptions from registration pursuant to Section 4(a)(2) under the Securities Act of 1933.


(d) EXHIBITS Exhibit No. Exhibit Description 10.1 Form of Warrant Exchange Agreement


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

International Stem Cell Corporation By: /s/ Jay NovakJay Novak Chief Financial Officer Dated: June 12, 2014

For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: Edgar Glimpses

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters